{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:03:55Z","timestamp":1792137835836,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.hoc.2017.05.003","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T20:30:21Z","timestamp":1498768221000},"page":"823-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gene Therapy Approaches to Immunodeficiency"],"prefix":"10.1016","volume":"31","author":[{"given":"Sujal","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bobby","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2017.05.003_bib1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"issue":"7","key":"10.1016\/j.hoc.2017.05.003_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/1744666X.2016.1150177","article-title":"Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future","volume":"12","author":"Booth","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.hoc.2017.05.003_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fimmu.2016.00314","article-title":"Adenosine deaminase deficiency - more than just an immunodeficiency","volume":"7","author":"Whitmore","year":"2016","journal-title":"Front Immunol"},{"issue":"97","key":"10.1016\/j.hoc.2017.05.003_bib4","doi-asserted-by":"crossref","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5235","key":"10.1016\/j.hoc.2017.05.003_bib5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T\u00a0lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"issue":"5235","key":"10.1016\/j.hoc.2017.05.003_bib6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients","volume":"270","author":"Bordignon","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.V91.1.30","article-title":"Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"91","author":"Onodera","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2017.05.003_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm0502-423","article-title":"Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement","volume":"8","author":"Aiuti","year":"2002","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2017.05.003_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2017.05.003_bib10","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2017.05.003_bib11","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2012-02-408591","article-title":"Gene therapy\/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction","volume":"120","author":"Carbonaro","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2017.05.003_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/humc.2016.29010.ind","article-title":"Investor outlook: rising from the ashes; GSK's European Approval of Strimvelis for ADA-SCID","volume":"27","author":"Schimmer","year":"2016","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"3","key":"10.1016\/j.hoc.2017.05.003_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/mt.2013.265","article-title":"Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency","volume":"22","author":"Carbonaro","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.05.003_bib14","unstructured":"Gaspar HB, Buckland K, Carbonaro DA, et\u00a0al. Immunological and metabolic correction after lentiviral vector gene therapy for ADA deficiency. Paper presented at: 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). New Orleans, LA, May 13\u201316, 2015."},{"key":"10.1016\/j.hoc.2017.05.003_bib15","doi-asserted-by":"crossref","first-page":"15061","DOI":"10.1038\/nrdp.2015.61","article-title":"Severe combined immunodeficiencies and related disorders","volume":"1","author":"Fischer","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"21","key":"10.1016\/j.hoc.2017.05.003_bib16","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJM199611213352104","article-title":"Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T\u00a0cells","volume":"335","author":"Stephan","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2017.05.003_bib17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex\u00a0vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2017.05.003_bib18","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"97","key":"10.1016\/j.hoc.2017.05.003_bib19","doi-asserted-by":"crossref","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T\u00a0cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2006-11-058933","article-title":"Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency","volume":"110","author":"Chinen","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2017.05.003_bib21","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1172\/JCI31659","article-title":"Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy","volume":"117","author":"Deichmann","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2017.05.003_bib22","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.hoc.2017.05.003_bib23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.mt.6300393","article-title":"Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency","volume":"16","author":"Thornhill","year":"2008","journal-title":"Mol Ther"},{"issue":"15","key":"10.1016\/j.hoc.2017.05.003_bib24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A\u00a0modified gamma-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2017.05.003_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2009-10-250209","article-title":"A\u00a0self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T\u00a0cells","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"issue":"335","key":"10.1016\/j.hoc.2017.05.003_bib26","doi-asserted-by":"crossref","first-page":"335ra357","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.hoc.2017.05.003_bib27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2013.05.031","article-title":"Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation","volume":"132","author":"Cole","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hoc.2012.11.002","article-title":"Chronic granulomatous disease","volume":"27","author":"Holland","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MOH.0b013e32834115e7","article-title":"Advances in the diagnosis and treatment of chronic granulomatous disease","volume":"18","author":"Seger","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2010.232","article-title":"Gene therapy of chronic granulomatous disease: the engraftment dilemma","volume":"19","author":"Grez","year":"2011","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaci.2015.11.028","article-title":"Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions","volume":"138","author":"Weisser","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"22","key":"10.1016\/j.hoc.2017.05.003_bib32","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1073\/pnas.94.22.12133","article-title":"Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease","volume":"94","author":"Malech","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2\u20133","key":"10.1016\/j.hoc.2017.05.003_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000072457","article-title":"Gene therapy for chronic granulomatous disease","volume":"110","author":"Goebel","year":"2003","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2017.05.003_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.hoc.2017.05.003_bib35","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-05-221606","article-title":"Restoration of NET formation by gene therapy in CGD controls aspergillosis","volume":"114","author":"Bianchi","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2017.05.003_bib36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2017.05.003_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2017.05.003_bib38","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jaci.2011.01.021","article-title":"Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent","volume":"127","author":"Bianchi","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.hoc.2017.05.003_bib39","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.hoc.2017.05.003_bib40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.coi.2012.07.012","article-title":"Gene therapy for primary immunodeficiencies: part 2","volume":"24","author":"Aiuti","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2017.05.003_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/asheducation-2009.1.132","article-title":"New insights into the biology of Wiskott-Aldrich syndrome (WAS)","author":"Thrasher","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2017.05.003_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/nyas.12049","article-title":"Wiskott-Aldrich syndrome: a comprehensive review","volume":"1285","author":"Massaad","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"3\u20134","key":"10.1016\/j.hoc.2017.05.003_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2010\/781523","article-title":"The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function","volume":"29","author":"Blundell","year":"2010","journal-title":"Dis Markers"},{"issue":"6","key":"10.1016\/j.hoc.2017.05.003_bib45","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2017.05.003_bib46","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"227","key":"10.1016\/j.hoc.2017.05.003_bib47","doi-asserted-by":"crossref","first-page":"227ra233","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.hoc.2017.05.003_bib48","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/mp200132u","article-title":"Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy","volume":"8","author":"Avedillo Diez","year":"2011","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.hoc.2017.05.003_bib49","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/hum.2006.17.303","article-title":"Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter\/cDNA-containing lentiviral vector and nonlethal irradiation","volume":"17","author":"Dupre","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.hoc.2017.05.003_bib50","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2009.31","article-title":"Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models","volume":"17","author":"Marangoni","year":"2009","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.hoc.2017.05.003_bib51","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jaci.2011.03.030","article-title":"Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome","volume":"127","author":"Bosticardo","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6148","key":"10.1016\/j.hoc.2017.05.003_bib52","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.hoc.2017.05.003_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1566523214666140918103731","article-title":"Gene therapy for Wiskott-Aldrich syndrome","volume":"14","author":"Bosticardo","year":"2014","journal-title":"Curr Gene Ther"},{"issue":"3","key":"10.1016\/j.hoc.2017.05.003_bib54","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2015.01.035","article-title":"B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome","volume":"136","author":"Castiello","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"15","key":"10.1016\/j.hoc.2017.05.003_bib55","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.hoc.2017.05.003_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(01)00309-9","article-title":"Artemis, a novel DNA double-strand break repair\/V(D)J recombination protein, is mutated in human severe combined immune deficiency","volume":"105","author":"Moshous","year":"2001","journal-title":"Cell"},{"issue":"5284","key":"10.1016\/j.hoc.2017.05.003_bib57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.274.5284.97","article-title":"RAG mutations in human B cell-negative SCID","volume":"274","author":"Schwarz","year":"1996","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.hoc.2017.05.003_bib58","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/mt.2008.118","article-title":"Stable and functional lymphoid reconstitution in Artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells","volume":"16","author":"Benjelloun","year":"2008","journal-title":"Mol Ther"},{"issue":"44","key":"10.1016\/j.hoc.2017.05.003_bib59","doi-asserted-by":"crossref","first-page":"16406","DOI":"10.1073\/pnas.0608130103","article-title":"Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer","volume":"103","author":"Mostoslavsky","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"10.1016\/j.hoc.2017.05.003_bib60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.mt.6300353","article-title":"Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients","volume":"16","author":"Lagresle-Peyrou","year":"2008","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.hoc.2017.05.003_bib61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/hum.2014.062","article-title":"Role of transgene regulation in ex\u00a0vivo lentiviral correction of artemis deficiency","volume":"26","author":"Multhaup","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/hum.2016.064","article-title":"Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency","volume":"28","author":"Punwani","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.hoc.2017.05.003_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-05-2032","article-title":"Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity","volume":"107","author":"Lagresle-Peyrou","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2017.05.003_bib64","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1182\/blood-2002-03-0782","article-title":"Gene therapy of RAG-2-\/- mice: sustained correction of the immunodeficiency","volume":"100","author":"Yates","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2017.05.003_bib65","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/leu.2011.106","article-title":"Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer","volume":"25","author":"Pike-Overzet","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2017.05.003_bib66","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/mt.2012.110","article-title":"Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene","volume":"20","author":"van Til","year":"2012","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.hoc.2017.05.003_bib67","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jaci.2013.10.009","article-title":"Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome","volume":"133","author":"van Til","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.hoc.2017.05.003_bib68","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood-2012-07-445858","article-title":"SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease","volume":"121","author":"Rivat","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2017.05.003_bib69","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/mt.2014.242","article-title":"Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency","volume":"23","author":"Carmo","year":"2015","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.hoc.2017.05.003_bib70","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1089\/hum.2016.065","article-title":"High level of perforin expression is required for effective correction of hemophagocytic lymphohistiocytosis","volume":"27","author":"Tiwari","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"317","key":"10.1016\/j.hoc.2017.05.003_bib71","doi-asserted-by":"crossref","first-page":"317ra198","DOI":"10.1126\/scitranslmed.aac8265","article-title":"Tracking genetically engineered lymphocytes long-term reveals the dynamics of T\u00a0cell immunological memory","volume":"7","author":"Oliveira","year":"2015","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.hoc.2017.05.003_bib72","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1089\/hum.2016.016","article-title":"Lentiviral vector-mediated correction of a mouse model of leukocyte adhesion deficiency type I","volume":"27","author":"Leon-Rico","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"215","key":"10.1016\/j.hoc.2017.05.003_bib73","doi-asserted-by":"crossref","first-page":"215ra174","DOI":"10.1126\/scitranslmed.3007320","article-title":"CD4(+) T\u00a0cells from IPEX patients convert into functional and stable regulatory T\u00a0cells by FOXP3 gene transfer","volume":"5","author":"Passerini","year":"2013","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.hoc.2017.05.003_bib74","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/3233","article-title":"Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice","volume":"4","author":"Brown","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2017.05.003_bib75","unstructured":"Schejtman A, Cutrim Arago Filho W, Zinicola M, et\u00a0al. Establishing the platform for clinical gene therapy of p47phox chronic granulomatous disease (CGD). Paper presented at: Changing the face of modern medicine: stem cells and gene therapy - 24th Annual Congress of European Society of Gene & Cell Therapy. Florence, Italy, October 18 \u2013 21, 2016."},{"key":"10.1016\/j.hoc.2017.05.003_bib76","unstructured":"Zinicola M, Schejtman A, Calero-Garcia M, et\u00a0al. Targeted gene therapy for the treatment of X-linked agammaglobulinemia (XLA). Paper presented at: Changing the face of modern medicine: stem cells and gene therapy - 24th Annual Congress of European Society of Gene & Cell Therapy. Florence, Italy, October 18 \u2013 21, 2016."}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881730093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985881730093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:55Z","timestamp":1760184295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985881730093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S088985881730093X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2017.05.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy Approaches to Immunodeficiency","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2017.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}